PF-06651600: all 46 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataRecruitingNCT07733765Phase 3
• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.RecruitingNCT07219615Phase 2
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataRecruitingNCT06873945Phase 3
• Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyRecruitingNCT06373458Phase 2
• A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy AdultsCompletedNCT06172348Phase 1Results posted
• A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult ParticipantsCompletedNCT05852340Phase 1Results posted
• A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgeCompletedNCT05650333Phase 1Results posted
• Ritlecitinib for Cicatricial AlopeciaCompletedNCT05549934Phase 2Results posted
• A Target Occupancy Study With Ritlecitinib.CompletedNCT05128058Phase 1Results posted
• Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of TolbutamideCompletedNCT05097716Phase 1Results posted
• A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy AdultsCompletedNCT05040295Phase 1Results posted
• PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATATerminatedNCT04517864Phase 2Results posted
• TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATECompletedNCT04413617Phase 2Results posted
• A Renal Impairment Study for PF-06651600TerminatedNCT04037865Phase 1Results posted
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy VolunteersCompletedNCT04016077Phase 1Results posted
• Long-Term PF-06651600 for the Treatment of Alopecia AreataCompletedNCT04006457Phase 3Results posted
• PF-06651600 for the Treatment of Alopecia AreataCompletedNCT03732807Phase 2/3Results posted
• A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo SubjectsCompletedNCT03715829Phase 2Results posted
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCompletedNCT03395184Phase 2Results posted
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataCompletedNCT02974868Phase 2Results posted
• Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To MethotrexateCompletedNCT02969044Phase 2Results posted
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02958865Phase 2Results posted
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.Active, not recruitingNCT07228390Phase 2
• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous UrticariaWithdrawnNCT06795373Phase 2
• A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without FoodCompletedNCT06369454Phase 1
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoActive, not recruitingNCT06163326Phase 3
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2Active, not recruitingNCT06072183Phase 3
• Ritlecitinib in CTCLTerminatedNCT05879458Phase 2
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingNCT05743244Phase 2
• Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in RemissionCompletedNCT05636293Phase 2
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloCompletedNCT05583526Phase 3
• PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTSCompletedNCT04634565Phase 1
• Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.CompletedNCT04390776Phase 1
• A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.CompletedNCT04355845Phase 1
• Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600CompletedNCT04266509Phase 1
• A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy ParticipantsCompletedNCT04092595Phase 1
• Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive SteroidsCompletedNCT04018274Phase 1
• Bioavailability Study of PF-06651600 Formulations in Healthy ParticipantsCompletedNCT04004663Phase 1
• Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.CompletedNCT03929510Phase 1
• PF-06651600 Taste Study.CompletedNCT03916393Phase 1
• A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTSCompletedNCT03827668Phase 1
• Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy ParticipantsCompletedNCT03821493Phase 1
• ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZCompletedNCT03762928Phase 1
• A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)CompletedNCT03608241Phase 1
• Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy VolunteersCompletedNCT03232905Phase 1
• Bioavailability Study Of PF-06651600 In Healthy SubjectsCompletedNCT02684760Phase 1

← PF-06651600 overview